Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | BRAF | P15056 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1899602 | 0.80 | NPC1 (0.40) | NPC1RAB9AKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL6910666 | 0.80 | NPC1 (0.40) | NPC1RAB9AKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL573387 | 0.75 | — | — | |
| SCHEMBL15122615 | 0.74 | NPC1 (0.42) | NPC1RAB9AKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL262314 | 0.73 | — | — | |
| SCHEMBL6809037 | 0.73 | — | — | |
| SCHEMBL28825040 | 0.72 | — | — | |
| SCHEMBL6158700 | 0.71 | — | — | |
| SCHEMBL22055452 | 0.71 | — | — | |
| SCHEMBL2321138 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9558863-B2 | Electrically conductive polymers with enhanced conductivity | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2017-01-31 | — | — | US | disclosed |
| US-9243111-B2 | Water-soluble electrically conductive polymers | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2016-01-26 | — | — | US | disclosed |
| US-20150083977-A1 | ELECTRICALLY CONDUCTIVE POLYMERS WITH ENHANCED CONDUCTIVITY | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2015-03-26 | — | — | US | disclosed |
| US-8920681-B2 | Electrically conductive polymers with enhanced conductivity | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2014-12-30 | — | — | US | disclosed |
| US-20140077135-A1 | WATER-SOLUBLE ELECTRICALLY CONDUCTIVE POLYMERS | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2014-03-20 | — | — | US | disclosed |
| US-8535571-B2 | Water-soluble electrically conductive polymers | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2013-09-17 | — | — | US | disclosed |
| US-8536300-B2 | Photocrosslinkable electrically conductive polymers | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2013-09-17 | — | — | US | disclosed |
| CN-102102114-B | Preparation of pregabalin and related compounds | WARNER LAMBERT CO | 2013-08-14 | — | — | CN | disclosed |
| US-8134023-B2 | Preparation of pregabalin and related compounds | PFIZER INC (US) | 2012-03-13 | — | — | US | disclosed |
| US-20120015412-A1 | Preparation of Pregabalin and Related Compounds | PFIZER INC | 2012-01-19 | — | — | US | disclosed |
| US-20090042262-A1 | Preparation of Pregabalin and Related Compounds | PFIZER INC | 2009-02-12 | — | — | US | disclosed |
| US-20080194841-A1 | Preparation of Optically Pure Beta-Amino Acids Having Affinity for the Alpha-Delta Protein | PFIZER INC. | 2008-08-14 | — | — | US | disclosed |
| WO-2008015516-A1 | FUSED TRICYCLIC HETEROCYCLES FOR THE TREATMENT OF SCHIZOPHRENIA | PFIZER PRODUCTS INC. (US) | 2008-02-07 | — | — | WO | disclosed |
| EP-1863780-A1 | PREPARATION OF OPTICALLY PURE BETA-AMINO ACIDS HAVING AFFINITY FOR THE ALPHA-2-DELTA PROTEIN | Pharmacia & Upjohn Company LLC (US) | 2007-12-12 | — | — | EP | disclosed |
| CN-101027278-A | Preparation of beta-amino acids having affinity for the alpha-2-delta protein | WARNER LAMBERT CO (US) | 2007-08-29 | — | — | CN | disclosed |
| US-20070141684-A1 | Preparation of gamma-amino acids having affinity for the alpha-2-delta protein | PFIZER INC | 2007-06-21 | — | — | US | disclosed |
| CN-1972904-A | Preparation of pregabalin and related compounds | WARNER LAMBERT CO (US) | 2007-05-30 | — | — | CN | disclosed |
| WO-2006100568-A1 | PREPARATION OF OPTICALLY PURE BETA-AMINO ACIDS HAVING AFFINITY FOR THE ALPHA-2-DELTA PROTEIN | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-09-28 | — | — | WO | disclosed |
| US-20050283023-A1 | Preparation of pregabalin and related compounds | HU SHANGHUI | 2005-12-22 | — | — | US | disclosed |
| US-20050228190-A1 | C1-symmetric bisphosphine ligands and their use in the asymmetric synthesis of pregabalin | BAO JIAN | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042262-A1 | Preparation of Pregabalin and Related Compounds | GABRE, GABRG1, GABRA6 | NPC1 3760/4885RAB9A 2336/4885KMT2A 2049/4885 |
| US-20070141684-A1 | Preparation of gamma-amino acids having affinity for the alpha-2-delta protein | SCN2A, CACNG2, SCN1A | NPC1 2810/4885RAB9A 1331/4885KMT2A 3394/4885 |
| US-20050283023-A1 | Preparation of pregabalin and related compounds | GABRE, GABRG1, GABRA6 | NPC1 3760/4885RAB9A 2336/4885KMT2A 2049/4885 |
| US-20050228190-A1 | C1-symmetric bisphosphine ligands and their use in the asymmetric synthesis of pregabalin | GABRA5, CNR1, GABRE | NPC1 2524/4885RAB9A 2968/4885KMT2A 3511/4885 |
| US-20080194841-A1 | Preparation of Optically Pure Beta-Amino Acids Having Affinity for the Alpha-Delta Protein | OPRD1, CHRND, CHRNE | NPC1 3527/4885RAB9A 1689/4885KMT2A 1405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.